(Health Korea News / Yoo Ji-in) On the 14th, Jeil Pharmaceutical successfully completed the launch symposium for its new drug for gastroesophageal reflux disease, ‘Jacubojeong’.
JaQbojeong (ingredient name: Jastaprazan) is a treatment for gastroesophageal reflux disease in the P-CAB (gastric acid secretion blocker) series approved by Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical, as the 37th new drug in Korea in April. Sales began on October 1 and successfully entered the market.
To commemorate the launch of JacQ Correction, this symposium has been held a total of 10 times since last September in major cities across the country, including Seoul, Incheon, and Suwon, as well as Daegu, Daejeon, Busan, and Gwangju. The symposium was designed to share the latest knowledge on gastroesophageal reflux disease and JAQ correction and to exchange various opinions on the P-CAB market.
An official from Jeil Pharmaceutical said, “Jaccubojeong, developed as Korea’s 37th new drug, has been receiving great attention in the market since its launch,” adding, “A total of 1,500 people attended the Jacubo symposium held in major cities across the country, demonstrating the excellence of Jacubo. “We were able to confirm the need,” he said.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
